

【Therapeutic category】 625 Anti-virus agents

【Non-proprietary name】 Bictegravir sodium/emtricitabine/tenofovir alafenamide fumarate

【Safety measure】 PRECAUTIONS should be revised.

A revised description is underlined.

Current			Revision		
2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)			2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)		
Patients receiving the following drugs: Rifampicin, carbamazepine, phenobarbital, phenytoin, fosphenytoin, apalutamide, food containing St. John's Wort, and enzalutamide			Patients receiving the following drugs: Rifampicin, carbamazepine, phenobarbital, phenytoin, fosphenytoin, apalutamide, food containing St. John's Wort, enzalutamide, <u>encorafenib</u> , <u>ivosidenib</u> , and <u>mitotane</u>		
10. INTERACTIONS			10. INTERACTIONS		
10.1 Contraindications for Co-administration (Do not co-administer with the following)			10.1 Contraindications for Co-administration (Do not co-administer with the following)		
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors
Enzalutamide	Since the plasma concentration of bictegravir decreases, the effect of this drug may decrease, and	Due to the CYP3A-inducing activity of <u>enzalutamide</u> .	Enzalutamide <u>Encorafenib</u> <u>Ivosidenib</u> <u>Mitotane</u>	Since the plasma concentration of bictegravir may decrease, the effect of this drug may decrease, and	Due to the CYP3A-inducing activity of <u>these drugs</u> .

	resistance to this drug may develop.				resistance to this drug may develop.	

This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.